Anteris Reports 2025 Financial Results and Provides Corporate Update

MINNEAPOLIS and BRISBANE, Australia, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: AVR, ASX: AVR), a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, today reported financial results for the full year ended December 31, 2025, and provided a corporate update. 2025 Full Year Highlights & Recent Developments Initiated the global pivotal PARADIGM Trial, building on experience from successfully treating 130 patients with the DurAVR® THV, including de novo (first time) aortic stenosis cases, complex anatomies and valve-in-valve patients Received FDA Investigational Device Exemption (“IDE”) approval in the fourth quarter of 2025 to initiate the PARADIGM Trial in the United States Reported favorable 30-day (100 patients) and 1-year (65 patients) DurAVR® THV clinical outcomes from rolling cohorts of small annuli, symptomatic severe aortic stenosis patients Completed the first “double DurAVR®” implant in a patient receiving a valve-in-valve replacement in both the mitral and aortic valve positions Strengthened operational infrastructure and advanced quality management system buildout while advancing manufacturing scale-up to support clinical activities, including ISO 13485 certification for DurAVR® THV production Appointed David Roberts and Gregory Moss to serve as two new independent directors on the Board of Directors Received approval from the Company's stockholders for ASX Limited's grant to the Company of a waiver from ASX Listing Rule 7.1 Completed aggregate capital raises totalling $320 million in early 2026, including a strategic investment from Medtronic, plc to support execution of the PARADIGM Trial and advance the Company toward global commercialization of the DurAVR® THV System “2025 was a pivotal year for Anteris, advancing DurAVR® with disciplined execution, strengthening our clinical foundation, and positioning the company for long term leadership in structural heart.

GlobeNewsWire • Feb 26, 2026

Anteris Technologies Global Corp. Announces Closing of $230 Million Public Offering of Common Stock

MINNEAPOLIS and BRISBANE, Australia, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: AVR, ASX: AVR), a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, today announced the closing of its underwritten public offering (the “Offering”) of 40,000,000 shares of its common stock, including the exercise in full of the underwriters' option to purchase additional shares from the Company (the “Shares”). The Shares were sold at a public offering price of $5.75 per share.

GlobeNewsWire • Jan 22, 2026

Anteris Announces Strategic Investment from Medtronic to Continue Advancing TAVR in $320 Million Aggregate Capital Raises

MINNEAPOLIS and BRISBANE, Australia, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ: AVR, ASX: AVR) a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, announced today it has completed a $90 million strategic investment from Medtronic, plc (Galway, Ireland) (NASDAQ: MDT) (Medtronic), the world's largest medical technology company. The investment closed immediately following Anteris' underwritten offering of common stock, for a combined $320 million in gross proceeds, which supports execution of the global pivotal PARADIGM trial and advances the Company toward global commercialization of the DurAVR® Transcatheter Heart Valve (THV).

GlobeNewsWire • Jan 22, 2026

Anteris Technologies Global Corp. Announces Pricing of $200 Million Public Offering

MINNEAPOLIS and BRISBANE, Australia, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: AVR, ASX: AVR), a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, today announced the pricing of its public offering (the “Offering”) of 34,782,609 shares of its common stock (the “Shares”). The Shares are being sold at a public offering price of $5.75 per share. The gross proceeds to the Company from the Offering, prior to deducting underwriting discounts, commissions and estimated offering expenses, are expected to be approximately $200 million. The Offering is expected to close on January 22, 2026, subject to the satisfaction of customary closing conditions.

GlobeNewsWire • Jan 21, 2026

Anteris Technologies Presents Data from 100 DurAVR® THV Patients at PCR London Valves

MINNEAPOLIS and BRISBANE, Australia, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ: AVR, ASX: AVR) today released 30-day clinical outcomes for the DurAVR® THV in one hundred severe aortic stenosis patients with small aortic annuli (aortic annulus area 404 ± 37mm2). The DurAVR® THV demonstrated single digit mean gradients, large effective orifice areas (EOAs), no moderate or severe paravalvular leaks and no valve related mortality, with 97% freedom from moderate or severe prosthesis-patient mismatch* (PPM) in a cohort of small annuli patients similar to the one reported in the SMART Trial1.

GlobeNewsWire • Nov 17, 2025

Anteris Announces Results for the Third Quarter of 2025

MINNEAPOLIS, Minn. and BRISBANE, Australia , Nov. 12, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ: AVR, ASX: AVR) a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, today reported financial results for the quarter ended September 30, 2025, and provided a corporate update.

GlobeNewsWire • Nov 12, 2025

Anteris Technologies Announces One-Year Clinical Outcomes for DurAVR® THV to be Presented at TCT® 2025

MINNEAPOLIS and BRISBANE, Australia, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ: AVR, ASX: AVR), a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, today announced that one-year clinical outcomes with the DurAVR® Transcatheter Heart Valve (THV) will be presented by Rishi Puri MD PhD, at TCT® 2025 – The 37th Annual Transcatheter Cardiovascular Therapeutics® Conference, taking place in San Francisco, California, October 25-28, 2025.

GlobeNewsWire • Oct 27, 2025

Anteris Technologies Announces First Patients Treated in DurAVR® THV Global Pivotal Trial (the “PARADIGM Trial”)

MINNEAPOLIS, United States and BRISBANE, Australia, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ: AVR, ASX: AVR) a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, today announced the first patients have been enrolled and successfully treated in the DurAVR® Transcatheter Heart Valve (THV) global pivotal trial for patients with severe calcific aortic stenosis (the “PARADIGM Trial”). The procedures were performed by Prof.

GlobeNewsWire • Oct 27, 2025

Anteris Technologies Global Corp. Announces Adjournment of Special Meeting of Stockholders

MINNEAPOLIS and BRISBANE, Australia, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ: AVR, ASX: AVR), a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, today announced that after convening its Special Meeting of Stockholders (the “Special Meeting”) virtually on Thursday, September 18, 2025, at 5:00 p.m.

GlobeNewsWire • Sep 19, 2025

Anteris Technologies Global Corp. Announces Postponement of Special Meeting of Stockholders

MINNEAPOLIS and BRISBANE, Australia, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ: AVR, ASX: AVR), a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, today announced that its Special Meeting of Stockholders (the “Special Meeting”), which was originally scheduled to be held on Thursday, September 11, 2025, at 5:00 p.m.

GlobeNewsWire • Sep 11, 2025